Do analysts rate OGI or THCX?

Organigram presently has a consensus price target of C$3.13, indicating a potential upside of 84.91%. Given Organigram's stronger consensus rating and higher probable upside, equities research analysts plainly believe Organigram is more favorable than Hydropothecary. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Organigram 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00 Hydropothecary 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Which has higher earnings and valuation, OGI or THCX?

Hydropothecary has lower revenue, but higher earnings than Organigram. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Organigram C$309.18M 0.77 -C$57.23M C$0.60 2.81 Hydropothecary N/A N/A N/A N/A N/A

Which has stronger earnings & valuation, OGI or GUD?

Knight Therapeutics has higher revenue and earnings than Organigram. Organigram is trading at a lower price-to-earnings ratio than Knight Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Organigram C$309.18M 0.77 -C$57.23M C$0.60 2.81 Knight Therapeutics C$547.31M 1.67 -C$30.73M C$0.15 62.13

Does the media favor OGI or GUD?

In the previous week, Organigram had 2 more articles in the media than Knight Therapeutics. MarketBeat recorded 3 mentions for Organigram and 1 mentions for Knight Therapeutics. Knight Therapeutics' average media sentiment score of 1.64 beat Organigram's score of 0.07 indicating that Knight Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Organigram 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Knight Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Which has preferable earnings and valuation, TLRY or OGI?

Organigram has lower revenue, but higher earnings than Tilray Brands. Tilray Brands is trading at a lower price-to-earnings ratio than Organigram, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Tilray Brands C$915.45M 0.96 -C$183.24M -C$1.09 N/A Organigram C$309.18M 0.77 -C$57.23M C$0.60 2.81

Does the media refer more to TLRY or OGI?

In the previous week, Organigram had 1 more articles in the media than Tilray Brands. MarketBeat recorded 3 mentions for Organigram and 2 mentions for Tilray Brands. Organigram's average media sentiment score of 0.07 beat Tilray Brands' score of -0.09 indicating that Organigram is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Tilray Brands 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Organigram 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts prefer OGI or CMED?

Organigram currently has a consensus target price of C$3.13, suggesting a potential upside of 84.91%. Given Organigram's stronger consensus rating and higher probable upside, analysts plainly believe Organigram is more favorable than CanniMed Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Organigram 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00 CanniMed Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Which has higher valuation and earnings, OGI or CMED?

CanniMed Therapeutics has lower revenue, but higher earnings than Organigram. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Organigram C$309.18M 0.77 -C$57.23M C$0.60 2.81 CanniMed Therapeutics N/A N/A N/A N/A N/A

Which has stronger earnings and valuation, WEED or OGI?

Organigram has higher revenue and earnings than Canopy Growth. Canopy Growth is trading at a lower price-to-earnings ratio than Organigram, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Canopy Growth C$293.63M 1.98 -C$1.05B -C$0.67 N/A Organigram C$309.18M 0.77 -C$57.23M C$0.60 2.81

Does the media refer more to WEED or OGI?

In the previous week, Organigram had 1 more articles in the media than Canopy Growth. MarketBeat recorded 3 mentions for Organigram and 2 mentions for Canopy Growth. Canopy Growth's average media sentiment score of 0.82 beat Organigram's score of 0.07 indicating that Canopy Growth is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Canopy Growth 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Organigram 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Organigram (OGI) Competitors

C$1.69 -0.06 (-3.43%)

As of 08/14/2026 04:00 PM Eastern

Compare

OGI vs. THCX, GUD, TLRY, CMED, and WEED

Should you buy Organigram stock or one of its competitors? Organigram's main competitors and comparable companies include Hydropothecary (THCX), Knight Therapeutics (GUD), Tilray Brands (TLRY), CanniMed Therapeutics (CMED), and Canopy Growth (WEED). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Organigram compare to Hydropothecary?

Organigram (TSE:OGI) and Hydropothecary (CVE:THCX) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their analyst recommendations, risk, valuation, earnings, profitability, media sentiment, institutional ownership and dividends.

Organigram has a net margin of 28.02% compared to Hydropothecary's net margin of 0.00%. Organigram's return on equity of 21.99% beat Hydropothecary's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Organigram	28.02%	21.99%	-5.56%
Hydropothecary	N/A	N/A	N/A

Organigram presently has a consensus price target of C$3.13, indicating a potential upside of 84.91%. Given Organigram's stronger consensus rating and higher probable upside, equities research analysts plainly believe Organigram is more favorable than Hydropothecary.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Organigram	0 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	3.00
Hydropothecary	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

In the previous week, Organigram had 3 more articles in the media than Hydropothecary. MarketBeat recorded 3 mentions for Organigram and 0 mentions for Hydropothecary. Organigram's average media sentiment score of 0.07 beat Hydropothecary's score of 0.00 indicating that Organigram is being referred to more favorably in the media.

Company	Overall Sentiment
Organigram	Neutral
Hydropothecary	Neutral

3.9% of Organigram shares are owned by institutional investors. 31.3% of Organigram shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Hydropothecary has lower revenue, but higher earnings than Organigram.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Organigram	C$309.18M	0.77	-C$57.23M	C$0.60	2.81
Hydropothecary	N/A	N/A	N/A	N/A	N/A

Summary

Organigram beats Hydropothecary on 10 of the 11 factors compared between the two stocks.

How does Organigram compare to Knight Therapeutics?

Organigram (TSE:OGI) and Knight Therapeutics (TSE:GUD) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their dividends, risk, analyst recommendations, earnings, profitability, media sentiment, institutional ownership and valuation.

In the previous week, Organigram had 2 more articles in the media than Knight Therapeutics. MarketBeat recorded 3 mentions for Organigram and 1 mentions for Knight Therapeutics. Knight Therapeutics' average media sentiment score of 1.64 beat Organigram's score of 0.07 indicating that Knight Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Organigram	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Knight Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Organigram has a beta of 1.443843, suggesting that its stock price is 44% more volatile than the broader market. Comparatively, Knight Therapeutics has a beta of -0.194384, suggesting that its stock price is 119% less volatile than the broader market.

Organigram presently has a consensus price target of C$3.13, indicating a potential upside of 84.91%. Knight Therapeutics has a consensus price target of C$9.50, indicating a potential upside of 1.93%. Given Organigram's higher probable upside, research analysts plainly believe Organigram is more favorable than Knight Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Organigram	0 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	3.00
Knight Therapeutics	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00

Organigram has a net margin of 28.02% compared to Knight Therapeutics' net margin of 2.72%. Organigram's return on equity of 21.99% beat Knight Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Organigram	28.02%	21.99%	-5.56%
Knight Therapeutics	2.72%	1.91%	0.51%

3.9% of Organigram shares are owned by institutional investors. Comparatively, 22.8% of Knight Therapeutics shares are owned by institutional investors. 31.3% of Organigram shares are owned by company insiders. Comparatively, 45.6% of Knight Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Knight Therapeutics has higher revenue and earnings than Organigram. Organigram is trading at a lower price-to-earnings ratio than Knight Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Organigram	C$309.18M	0.77	-C$57.23M	C$0.60	2.81
Knight Therapeutics	C$547.31M	1.67	-C$30.73M	C$0.15	62.13

Summary

Knight Therapeutics beats Organigram on 8 of the 15 factors compared between the two stocks.

How does Organigram compare to Tilray Brands?

Tilray Brands (TSE:TLRY) and Organigram (TSE:OGI) are both small-cap healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their dividends, earnings, institutional ownership, risk, media sentiment, valuation, profitability and analyst recommendations.

In the previous week, Organigram had 1 more articles in the media than Tilray Brands. MarketBeat recorded 3 mentions for Organigram and 2 mentions for Tilray Brands. Organigram's average media sentiment score of 0.07 beat Tilray Brands' score of -0.09 indicating that Organigram is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Tilray Brands	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Organigram	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Organigram has lower revenue, but higher earnings than Tilray Brands. Tilray Brands is trading at a lower price-to-earnings ratio than Organigram, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Tilray Brands	C$915.45M	0.96	-C$183.24M	-C$1.09	N/A
Organigram	C$309.18M	0.77	-C$57.23M	C$0.60	2.81

Tilray Brands currently has a consensus price target of C$13.30, suggesting a potential upside of 105.88%. Organigram has a consensus price target of C$3.13, suggesting a potential upside of 84.91%. Given Tilray Brands' higher probable upside, equities analysts clearly believe Tilray Brands is more favorable than Organigram.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Tilray Brands	0 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00
Organigram	0 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	3.00

Tilray Brands has a beta of 2.949831, indicating that its stock price is 195% more volatile than the broader market. Comparatively, Organigram has a beta of 1.443843, indicating that its stock price is 44% more volatile than the broader market.

4.6% of Tilray Brands shares are owned by institutional investors. Comparatively, 3.9% of Organigram shares are owned by institutional investors. 0.7% of Tilray Brands shares are owned by company insiders. Comparatively, 31.3% of Organigram shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Organigram has a net margin of 28.02% compared to Tilray Brands' net margin of -15.22%. Organigram's return on equity of 21.99% beat Tilray Brands' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Tilray Brands	-15.22%	-8.85%	-1.41%
Organigram	28.02%	21.99%	-5.56%

Summary

Organigram beats Tilray Brands on 10 of the 16 factors compared between the two stocks.

How does Organigram compare to CanniMed Therapeutics?

Organigram (TSE:OGI) and CanniMed Therapeutics (TSE:CMED) are both small-cap healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their earnings, media sentiment, profitability, valuation, institutional ownership, dividends, risk and analyst recommendations.

Organigram currently has a consensus target price of C$3.13, suggesting a potential upside of 84.91%. Given Organigram's stronger consensus rating and higher probable upside, analysts plainly believe Organigram is more favorable than CanniMed Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Organigram	0 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	3.00
CanniMed Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

3.9% of Organigram shares are held by institutional investors. 31.3% of Organigram shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Organigram has a net margin of 28.02% compared to CanniMed Therapeutics' net margin of 0.00%. Organigram's return on equity of 21.99% beat CanniMed Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Organigram	28.02%	21.99%	-5.56%
CanniMed Therapeutics	N/A	N/A	N/A

In the previous week, Organigram had 3 more articles in the media than CanniMed Therapeutics. MarketBeat recorded 3 mentions for Organigram and 0 mentions for CanniMed Therapeutics. Organigram's average media sentiment score of 0.07 beat CanniMed Therapeutics' score of 0.00 indicating that Organigram is being referred to more favorably in the media.

Company	Overall Sentiment
Organigram	Neutral
CanniMed Therapeutics	Neutral

CanniMed Therapeutics has lower revenue, but higher earnings than Organigram.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Organigram	C$309.18M	0.77	-C$57.23M	C$0.60	2.81
CanniMed Therapeutics	N/A	N/A	N/A	N/A	N/A

Summary

Organigram beats CanniMed Therapeutics on 10 of the 11 factors compared between the two stocks.

How does Organigram compare to Canopy Growth?

Canopy Growth (TSE:WEED) and Organigram (TSE:OGI) are both small-cap healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their media sentiment, institutional ownership, dividends, earnings, risk, analyst recommendations, valuation and profitability.

Organigram has a net margin of 28.02% compared to Canopy Growth's net margin of -73.95%. Organigram's return on equity of 21.99% beat Canopy Growth's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Canopy Growth	-73.95%	-29.85%	-3.83%
Organigram	28.02%	21.99%	-5.56%

4.1% of Canopy Growth shares are owned by institutional investors. Comparatively, 3.9% of Organigram shares are owned by institutional investors. 0.2% of Canopy Growth shares are owned by company insiders. Comparatively, 31.3% of Organigram shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Canopy Growth currently has a consensus price target of C$1.88, suggesting a potential upside of 35.87%. Organigram has a consensus price target of C$3.13, suggesting a potential upside of 84.91%. Given Organigram's stronger consensus rating and higher possible upside, analysts plainly believe Organigram is more favorable than Canopy Growth.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Canopy Growth	0 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.67
Organigram	0 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	3.00

In the previous week, Organigram had 1 more articles in the media than Canopy Growth. MarketBeat recorded 3 mentions for Organigram and 2 mentions for Canopy Growth. Canopy Growth's average media sentiment score of 0.82 beat Organigram's score of 0.07 indicating that Canopy Growth is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Canopy Growth	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Organigram	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Organigram has higher revenue and earnings than Canopy Growth. Canopy Growth is trading at a lower price-to-earnings ratio than Organigram, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Canopy Growth	C$293.63M	1.98	-C$1.05B	-C$0.67	N/A
Organigram	C$309.18M	0.77	-C$57.23M	C$0.60	2.81

Canopy Growth has a beta of 1.382001, suggesting that its stock price is 38% more volatile than the broader market. Comparatively, Organigram has a beta of 1.443843, suggesting that its stock price is 44% more volatile than the broader market.

Summary

Organigram beats Canopy Growth on 11 of the 15 factors compared between the two stocks.

Get Organigram News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

Media Sentiment Over Time

This chart shows the average media sentiment of TSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

OGI vs. The Competition

Export

Metric	Organigram	Pharmaceuticals Industry	Healthcare Sector	TSE Exchange
Market Cap	C$246.36M	C$11.82B	C$7.04B	C$12.73B
Dividend Yield	N/A	2.70%	2.57%	6.20%
P/E Ratio	2.81	779.99	271.26	37.73
Price / Sales	0.77	749.01	623.04	9.73
Price / Cash	3.85	89.04	75.70	82.29
Price / Book	0.47	11.60	12.92	4.58
Net Income	-C$57.23M	C$2.77B	C$3.45B	C$299.09M
7 Day Performance	23.36%	0.14%	1.16%	0.93%
1 Month Performance	37.40%	0.06%	1.37%	4.00%
1 Year Performance	-15.92%	145.15%	62.53%	35.62%

Organigram Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
OGI Organigram	4.2477 of 5 stars	C$1.69 -3.4%	C$3.13 +84.9%	-21.0%	C$246.36M	C$309.18M	2.81	987
THCX Hydropothecary	N/A	C$5.30 +6.6%	N/A	+0.0%	C$949.11M	N/A	N/A	N/A	High Trading Volume
GUD Knight Therapeutics	1.0946 of 5 stars	C$9.37 -1.4%	C$9.50 +1.4%	+49.1%	C$920.43M	C$510.45M	156.17	725	Positive News
TLRY Tilray Brands	1.3081 of 5 stars	C$6.46 -2.4%	C$13.30 +105.9%	-60.4%	C$879.88M	C$915.45M	N/A	2,650
CMED CanniMed Therapeutics	N/A	N/A	N/A	N/A	C$668.44M	N/A	N/A	147,000

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (TSE:OGI) was last updated on 8/15/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Organigram (OGI) Competitors

OGI vs. THCX, GUD, TLRY, CMED, and WEED

How does Organigram compare to Hydropothecary?

Summary

How does Organigram compare to Knight Therapeutics?

Summary

How does Organigram compare to Tilray Brands?

Summary

How does Organigram compare to CanniMed Therapeutics?

Summary

How does Organigram compare to Canopy Growth?

Summary

Media Sentiment Over Time

OGI vs. The Competition

Organigram Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Organigram (OGI) Competitors

OGI vs. THCX, GUD, TLRY, CMED, and WEED

How does Organigram compare to Hydropothecary?

Is OGI or THCX more profitable?

Do analysts rate OGI or THCX?

Does the media favor OGI or THCX?

Do institutionals and insiders hold more shares of OGI or THCX?

Which has higher earnings and valuation, OGI or THCX?

Summary

How does Organigram compare to Knight Therapeutics?

Does the media favor OGI or GUD?

Which has more risk and volatility, OGI or GUD?

Do analysts rate OGI or GUD?

Is OGI or GUD more profitable?

Do insiders & institutionals believe in OGI or GUD?

Which has stronger earnings & valuation, OGI or GUD?

Summary

How does Organigram compare to Tilray Brands?

Does the media refer more to TLRY or OGI?

Which has preferable earnings and valuation, TLRY or OGI?

Do analysts prefer TLRY or OGI?

Which has more risk and volatility, TLRY or OGI?

Do insiders and institutionals hold more shares of TLRY or OGI?

Is TLRY or OGI more profitable?

Summary

How does Organigram compare to CanniMed Therapeutics?

Do analysts prefer OGI or CMED?

Do insiders & institutionals have more ownership in OGI or CMED?

Is OGI or CMED more profitable?

Does the media prefer OGI or CMED?

Which has higher valuation and earnings, OGI or CMED?

Summary

How does Organigram compare to Canopy Growth?

Is WEED or OGI more profitable?

Do institutionals and insiders have more ownership in WEED or OGI?

Do analysts recommend WEED or OGI?

Does the media refer more to WEED or OGI?

Which has stronger earnings and valuation, WEED or OGI?

Which has more volatility and risk, WEED or OGI?

Summary

Media Sentiment Over Time

OGI vs. The Competition

Organigram Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools